Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Operating Margin: 2017-2025

Historic Operating Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 17.57%.

  • Puma Biotechnology's Operating Margin fell 984.00% to 17.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.83%, marking a year-over-year increase of 253.00%. This contributed to the annual value of 13.44% for FY2024, which is 42.00% down from last year.
  • Puma Biotechnology's Operating Margin amounted to 17.57% in Q3 2025, which was up 38.86% from 12.66% recorded in Q2 2025.
  • Puma Biotechnology's Operating Margin's 5-year high stood at 27.41% during Q3 2024, with a 5-year trough of -31.16% in Q2 2021.
  • For the 3-year period, Puma Biotechnology's Operating Margin averaged around 12.01%, with its median value being 12.66% (2025).
  • Per our database at Business Quant, Puma Biotechnology's Operating Margin slumped by 4,126bps in 2021 and then spiked by 5,142bps in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Operating Margin stood at -0.91% in 2021, then surged by 1,234bps to 11.43% in 2022, then spiked by 907bps to 20.50% in 2023, then skyrocketed by 212bps to 22.62% in 2024, then slumped by 984bps to 17.57% in 2025.
  • Its Operating Margin stands at 17.57% for Q3 2025, versus 12.66% for Q2 2025 and 8.66% for Q1 2025.